While sexism exists in all strands of society, where in 2023, women earn 77 cents for every dollar earned by men, studies estimate that it will take the world 257…
Researchers in Germany have discovered a mechanism by which cancer cells escape the immune system - and how to reverse it. Triple-negative breast cancer (TNBC) is the most aggressive and…
There are several promising new vaccine candidates being developed for complex diseases that historically have been extremely difficult to find treatments and cures for. The development of these new vaccines…
Understanding invasive cancer progression and metastasis formation are among the core open questions in cancer research. However, the limitations of current models lead to high failure rates in drug development.…
Researchers from global health system Cleveland Clinic have launched the next step in their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal…
The Menarini Group, an Italian pharmaceutical and diagnostics company, says that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men,…
Ibex Medical Analytics has announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate…
Phesi, a global provider of patient-centric data analytics, has released the results of its global analysis of all clinical trials conducted in 2022. The report, which analyzed 80,917 trial records, reveals…
ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de…
Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s…
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy…
Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase…
Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies, is set to complete the regulatory nonclinical package allowing entry in clinical trials. The company,…
Results of a cancer treatment in the treatment of gynecologic and breast cancer are to be presented next week, November 8-12, at the Society for Immunotherapy of Cancer (SITC) conference…
Results from a phase 1b study of a drug to treat patients with androgen receptor positive (AR+) metastatic breast cancer (mBC) in China were published yesterday (September 28). Kintor Pharmaceutical…
Roche has signed a memorandum of understanding (MoU) with the Johns Hopkins Program for International Education in Gynecology and Obstetrics (Jhpiego) to improve cervical and breast cancer outcomes in resource-constrained…
Reveal Genomics, S.L. says it has received more validation of HER2DX, the world's first specialized genomic test for HER2+ breast cancer. Valentina Guarneri from the University of Padova presented the…
Top line results from a clinical trial treating breast cancer patients with radiation dermatitis (RD) have been positive. Lutris Pharma, based in Israel, is a biopharma company focused on improving…
Ibex Medical Analytics have just announced positive outcomes for its Galen Breast solution in diagnosing multiple cancer types and further expanding its portfolio for breast cancer diagnosis. The CE-marked artificial-intelligence…
All of Everest Medicine's development and commercialization rights for a breast cancer drug called Trodelvy have been transferred to American biopharma Gilead Sciences Inc. The transfer of the antibody drug,…